PPD's X-Chem strikes another deal with Bayer

X-Chem, the biotech that operates from within PPD, signed a second agreement with partner Bayer, outlicensing a second discovery-stage program. The two have been working together since 2012 in a multitarget collaboration. Under the latest deal, gets an undisclosed upfront fee and milestones down the line in exchange for some small-molecule candidates that target cardiovascular disease. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.